Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2016–2020

ESA -ITN · European Sepsis Academy: towards new biomarkers to improve sepsis management

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2016-03-01 → 2020-02-29
Финансиране от ЕС
3 895 551 €
Участници
8
Схема
MSCA-ITN-ETN

Линиите свързват координатора с партньорите.

Накратко на български

Биомаркерите и молекулярните промени при сепсис помагат за разпознаване на фазата, в която имунната система е потисната. Това е важно за по-бърза диагностика и прилагане на персонализирано лечение при тежките инфекции.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

European Sepsis Academy: towards new biomarkers to improve sepsis management

Sepsis, a severe life-threatening infection with organ dysfunction (affecting ~18 million individuals, with a high mortality rate) initiates a complex interplay of host pro- and anti-inflammatory processes. Key priorities in treating sepsis are; 1) recognising 'sepsis' as such 2) identification of the source and type of the infection 3) identification of the stage of disease 4) initiation of early targeted treatment The European Sepsis Academy (ESA) aimed to develop and validate the pathological insights, biomarker diagnostics and clinical trial models to enable development and implementation of personalised treatment strategies, targeted at the immunosuppressive phase of sepsis: 1. Describing the pathogenesis of sepsis-induced immune suppression (SIIS) at the level of immune regulatory molecules and DNA methylation 2. Discovery: To identify and validate biomarkers to be used for clinical diagnosis and monitoring of SIIS. 3. Development: To prepare and optimise high-potential diagnostic technology and test innovative clinical trial designs.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

ESA-ITN will break through the state of the art in sepsis diagnostics and will train 15 early-stage researchers (ESRs) todetermine the clinical potency of a variety of new complementary sepsis biomarkers. These cover the full range of the antiinflammatory response in sepsis, at genetic, molecular and cellular level. Rapid and practical biomarker diagnostics forsepsis will be developed by building on some of the world's most innovative diagnostic platforms. In addition, a whole newclinical research model that incorporates use of biomarker diagnostics will be designed and tested.All 15 interlinked ESR projects have an interdisciplinary component (intersection of sepsis research, product development,economics and medical practice) and international (representing 10 countries) and industry collaborations (incorporating 3diagnostics firms, 1 bioinformatics company and a business school). Interactions within the network are strengthened bymeaningful secondments, which take place at private beneficiary or partner institutes.The training programme covers:1. Specialist training in an international, interdisciplinary and intersectorial sepsis-orientated research project;2. Advanced technology training in pathogenesis, biomarker discovery, diagnostics, trial design and innovation management;3. Professional training in transferable skills, including the special ESA-ITN mini-MBA.The setup of ESA-ITN is unique as it reflects the entire innovation value chain for sepsis biomarker diagnostics. ESA-ITN iscomposed of leading institutes in sepsis research and a selection of Europe's top biomarker diagnostics companies. Links tovarious global networks and shared research infrastructures in the field of sepsis further leverage the proposition of ESA-ITN.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз